Cargando…

Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies

Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people (IDP) has focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers (HV), antispike immunoglobulin G (IgG) was detected in 88% of IDP after dose 2, incre...

Descripción completa

Detalles Bibliográficos
Autores principales: Zendt, Mackenzie, Bustos Carrillo, Fausto A., Kelly, Sophie, Saturday, Taylor, DeGrange, Maureen, Ginigeme, Anita, Wu, Lurline, Callier, Viviane, Ortega-Villa, Ana, Faust, Mondreakest, Chang-Rabley, Emma, Bugal, Kara, Kenney, Heather, Khil, Pavel, Youn, Jung-Ho, Osei, Gloria, Regmi, Pravesh, Anderson, Victoria, Bosticardo, Marita, Daub, Janine, DiMaggio, Thomas, Kreuzburg, Samantha, Pala, Francesca, Pfister, Justina, Treat, Jennifer, Ulrick, Jean, Karkanitsa, Maria, Kalish, Heather, Kuhns, Douglas B., Priel, Debra L., Fink, Danielle L., Tsang, John S., Sparks, Rachel, Uzel, Gulbu, Waldman, Meryl A., Zerbe, Christa S., Delmonte, Ottavia M., Bergerson, Jenna R. E., Das, Sanchita, Freeman, Alexandra F., Lionakis, Michail S., Sadtler, Kaitlyn, van Doremalen, Neeltje, Munster, Vincent, Notarangelo, Luigi D., Holland, Steven M., Ricotta, Emily E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for the Advancement of Science 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569702/
https://www.ncbi.nlm.nih.gov/pubmed/37824621
http://dx.doi.org/10.1126/sciadv.adh3150
_version_ 1785119605264482304
author Zendt, Mackenzie
Bustos Carrillo, Fausto A.
Kelly, Sophie
Saturday, Taylor
DeGrange, Maureen
Ginigeme, Anita
Wu, Lurline
Callier, Viviane
Ortega-Villa, Ana
Faust, Mondreakest
Chang-Rabley, Emma
Bugal, Kara
Kenney, Heather
Khil, Pavel
Youn, Jung-Ho
Osei, Gloria
Regmi, Pravesh
Anderson, Victoria
Bosticardo, Marita
Daub, Janine
DiMaggio, Thomas
Kreuzburg, Samantha
Pala, Francesca
Pfister, Justina
Treat, Jennifer
Ulrick, Jean
Karkanitsa, Maria
Kalish, Heather
Kuhns, Douglas B.
Priel, Debra L.
Fink, Danielle L.
Tsang, John S.
Sparks, Rachel
Uzel, Gulbu
Waldman, Meryl A.
Zerbe, Christa S.
Delmonte, Ottavia M.
Bergerson, Jenna R. E.
Das, Sanchita
Freeman, Alexandra F.
Lionakis, Michail S.
Sadtler, Kaitlyn
van Doremalen, Neeltje
Munster, Vincent
Notarangelo, Luigi D.
Holland, Steven M.
Ricotta, Emily E.
author_facet Zendt, Mackenzie
Bustos Carrillo, Fausto A.
Kelly, Sophie
Saturday, Taylor
DeGrange, Maureen
Ginigeme, Anita
Wu, Lurline
Callier, Viviane
Ortega-Villa, Ana
Faust, Mondreakest
Chang-Rabley, Emma
Bugal, Kara
Kenney, Heather
Khil, Pavel
Youn, Jung-Ho
Osei, Gloria
Regmi, Pravesh
Anderson, Victoria
Bosticardo, Marita
Daub, Janine
DiMaggio, Thomas
Kreuzburg, Samantha
Pala, Francesca
Pfister, Justina
Treat, Jennifer
Ulrick, Jean
Karkanitsa, Maria
Kalish, Heather
Kuhns, Douglas B.
Priel, Debra L.
Fink, Danielle L.
Tsang, John S.
Sparks, Rachel
Uzel, Gulbu
Waldman, Meryl A.
Zerbe, Christa S.
Delmonte, Ottavia M.
Bergerson, Jenna R. E.
Das, Sanchita
Freeman, Alexandra F.
Lionakis, Michail S.
Sadtler, Kaitlyn
van Doremalen, Neeltje
Munster, Vincent
Notarangelo, Luigi D.
Holland, Steven M.
Ricotta, Emily E.
author_sort Zendt, Mackenzie
collection PubMed
description Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people (IDP) has focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers (HV), antispike immunoglobulin G (IgG) was detected in 88% of IDP after dose 2, increasing to 93% by 6 months after dose 3. Despite high seroconversion, median IgG levels for IDP never surpassed one-third that of HV. IgG binding to Omicron BA.1 was lowest among variants. Angiotensin-converting enzyme 2 pseudo-neutralization only modestly correlated with antispike IgG concentration. IgG levels were not significantly altered by receipt of different messenger RNA–based vaccines, immunomodulating treatments, and prior severe acute respiratory syndrome coronavirus 2 infections. While our data show that three doses of coronavirus disease 2019 vaccinations induce antispike IgG in most IDP, additional doses are needed to increase protection. Because of the notably reduced IgG response to Omicron BA.1, the efficacy of additional vaccinations, including bivalent vaccines, should be studied in this population.
format Online
Article
Text
id pubmed-10569702
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher American Association for the Advancement of Science
record_format MEDLINE/PubMed
spelling pubmed-105697022023-10-13 Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies Zendt, Mackenzie Bustos Carrillo, Fausto A. Kelly, Sophie Saturday, Taylor DeGrange, Maureen Ginigeme, Anita Wu, Lurline Callier, Viviane Ortega-Villa, Ana Faust, Mondreakest Chang-Rabley, Emma Bugal, Kara Kenney, Heather Khil, Pavel Youn, Jung-Ho Osei, Gloria Regmi, Pravesh Anderson, Victoria Bosticardo, Marita Daub, Janine DiMaggio, Thomas Kreuzburg, Samantha Pala, Francesca Pfister, Justina Treat, Jennifer Ulrick, Jean Karkanitsa, Maria Kalish, Heather Kuhns, Douglas B. Priel, Debra L. Fink, Danielle L. Tsang, John S. Sparks, Rachel Uzel, Gulbu Waldman, Meryl A. Zerbe, Christa S. Delmonte, Ottavia M. Bergerson, Jenna R. E. Das, Sanchita Freeman, Alexandra F. Lionakis, Michail S. Sadtler, Kaitlyn van Doremalen, Neeltje Munster, Vincent Notarangelo, Luigi D. Holland, Steven M. Ricotta, Emily E. Sci Adv Biomedicine and Life Sciences Research on coronavirus disease 2019 vaccination in immune-deficient/disordered people (IDP) has focused on cancer and organ transplantation populations. In a prospective cohort of 195 IDP and 35 healthy volunteers (HV), antispike immunoglobulin G (IgG) was detected in 88% of IDP after dose 2, increasing to 93% by 6 months after dose 3. Despite high seroconversion, median IgG levels for IDP never surpassed one-third that of HV. IgG binding to Omicron BA.1 was lowest among variants. Angiotensin-converting enzyme 2 pseudo-neutralization only modestly correlated with antispike IgG concentration. IgG levels were not significantly altered by receipt of different messenger RNA–based vaccines, immunomodulating treatments, and prior severe acute respiratory syndrome coronavirus 2 infections. While our data show that three doses of coronavirus disease 2019 vaccinations induce antispike IgG in most IDP, additional doses are needed to increase protection. Because of the notably reduced IgG response to Omicron BA.1, the efficacy of additional vaccinations, including bivalent vaccines, should be studied in this population. American Association for the Advancement of Science 2023-10-12 /pmc/articles/PMC10569702/ /pubmed/37824621 http://dx.doi.org/10.1126/sciadv.adh3150 Text en Copyright © 2023 The Authors, some rights reserved; exclusive licensee American Association for the Advancement of Science. No claim to original U.S. Government Works. Distributed under a Creative Commons Attribution License 4.0 (CC BY). https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution license (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Biomedicine and Life Sciences
Zendt, Mackenzie
Bustos Carrillo, Fausto A.
Kelly, Sophie
Saturday, Taylor
DeGrange, Maureen
Ginigeme, Anita
Wu, Lurline
Callier, Viviane
Ortega-Villa, Ana
Faust, Mondreakest
Chang-Rabley, Emma
Bugal, Kara
Kenney, Heather
Khil, Pavel
Youn, Jung-Ho
Osei, Gloria
Regmi, Pravesh
Anderson, Victoria
Bosticardo, Marita
Daub, Janine
DiMaggio, Thomas
Kreuzburg, Samantha
Pala, Francesca
Pfister, Justina
Treat, Jennifer
Ulrick, Jean
Karkanitsa, Maria
Kalish, Heather
Kuhns, Douglas B.
Priel, Debra L.
Fink, Danielle L.
Tsang, John S.
Sparks, Rachel
Uzel, Gulbu
Waldman, Meryl A.
Zerbe, Christa S.
Delmonte, Ottavia M.
Bergerson, Jenna R. E.
Das, Sanchita
Freeman, Alexandra F.
Lionakis, Michail S.
Sadtler, Kaitlyn
van Doremalen, Neeltje
Munster, Vincent
Notarangelo, Luigi D.
Holland, Steven M.
Ricotta, Emily E.
Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
title Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
title_full Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
title_fullStr Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
title_full_unstemmed Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
title_short Characterization of the antispike IgG immune response to COVID-19 vaccines in people with a wide variety of immunodeficiencies
title_sort characterization of the antispike igg immune response to covid-19 vaccines in people with a wide variety of immunodeficiencies
topic Biomedicine and Life Sciences
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10569702/
https://www.ncbi.nlm.nih.gov/pubmed/37824621
http://dx.doi.org/10.1126/sciadv.adh3150
work_keys_str_mv AT zendtmackenzie characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT bustoscarrillofaustoa characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT kellysophie characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT saturdaytaylor characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT degrangemaureen characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT ginigemeanita characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT wulurline characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT callierviviane characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT ortegavillaana characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT faustmondreakest characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT changrableyemma characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT bugalkara characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT kenneyheather characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT khilpavel characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT younjungho characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT oseigloria characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT regmipravesh characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT andersonvictoria characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT bosticardomarita characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT daubjanine characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT dimaggiothomas characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT kreuzburgsamantha characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT palafrancesca characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT pfisterjustina characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT treatjennifer characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT ulrickjean characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT karkanitsamaria characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT kalishheather characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT kuhnsdouglasb characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT prieldebral characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT finkdaniellel characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT tsangjohns characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT sparksrachel characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT uzelgulbu characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT waldmanmeryla characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT zerbechristas characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT delmonteottaviam characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT bergersonjennare characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT dassanchita characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT freemanalexandraf characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT lionakismichails characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT sadtlerkaitlyn characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT vandoremalenneeltje characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT munstervincent characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT notarangeloluigid characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT hollandstevenm characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies
AT ricottaemilye characterizationoftheantispikeiggimmuneresponsetocovid19vaccinesinpeoplewithawidevarietyofimmunodeficiencies